Mar 16, 2021 8:30 am EDT Skye Bioscience’s Cannabinoid-Derived Drug Candidate, THCVHS, Demonstrates No Eye Irritation in Preclinical Assessment
Mar 8, 2021 8:39 am EST Skye Bioscience Appoints Cannabinoid Science Experts Giovanni Appendino, PhD and Eduardo Muñoz, MD, PhD to Scientific Advisory Board
Mar 3, 2021 8:37 am EST Skye Bioscience to Present at H.C. Wainwright Global Life Sciences Conference
Jan 19, 2021 8:30 am EST Emerald Bioscience Launches Rebrand Including Name Change to Skye Bioscience
Jan 15, 2021 1:30 pm EST Emerald Bioscience to Change Name and Trading Symbol Effective Tuesday, January 19th
Dec 16, 2020 8:30 am EST Emerald Bioscience Reports that Superior Reduction of Intraocular Pressure of its Unique Nanoemulsion Formulation of THCVHS is Published in Peer-Reviewed Journal
Dec 7, 2020 8:44 am EST Emerald Bioscience to Present at the Benzinga Global Small Cap Virtual Conference